GlassScriptPhysician profile
Pria Vattamparambil
NPI 1053995258
$1,616.78
in general payments reported to CMS, 2019-2025
11 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $126 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $442.08 | 2025 | Bimzelx, Cimzia |
| Amgen INC. | $284.08 | 2025 | Evenity, Otezla, Uplizna |
| Pfizer INC. | $239.02 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $171.00 | 2024-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $151.33 | 2025 | Benlysta |
| Abbvie INC. | $115.83 | 2025 | |
| Janssen Biotech, INC. | $99.41 | 2025 | Tremfya |
| Sobi, INC | $36.40 | 2025 | |
| Atland Pharmaceuticals, LLC | $34.13 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Sandoz INC. | $23.14 | 2025 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $20.36 | 2025 | Sovuna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pria Vattamparambil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.